An industry-funded trial found that ubrogepant was associated with absence of moderate or severe headache within 24 hours 46% of the time versus 29% with placebo when taken during the prodrome period (nonaura symptoms preceding headache onset).
21 Nov 2023
A shift in diagnostic approach for vertigo involves asking about the timing and triggers for episodes rather than a description of symptoms.
1 Jan 2024
Collecting good data is the first step in sorting through the many drugs and devices that are used to treat migraines.
1 Jul 2019
An industry-funded trial found that migraine pain resolved sooner with eptinezumab than placebo, while a meta-analysis found that several established and newer therapies for the acute treatment of migraine were associated with reductions in short-term pain.
22 Jun 2021
New drugs take aim at migraine prevention, but long-term effects are uncertain.
1 Oct 2018
While mindfulness-based stress reduction did not improve migraine frequency more than headache education in a small randomized trial, it significantly improved disability, quality of life, self-efficacy, pain catastrophizing, and depression out to 36 weeks.
22 Dec 2020
Erenumab reduced migraines in patients who didn't respond to other treatments, industry-funded study found
An industry-funded study found improvements in primary and secondary endpoints related to migraines with the drug compared to placebo, with similar safety and tolerability.
30 Oct 2018
CMS released a proposed rule to address the administrative hassles of prior authorizations in Medicare Advantage plans, calling for automated processes, shorter decision-making time frames, and more transparency about the services subject to prior authorizations.
1 Nov 2023
Higher absolute risks of cardiovascular disease were observed among patients with migraine across most outcomes and follow-up periods during 19 years of follow-up.
6 Feb 2018
This column reviews recent recalls, alerts, and approvals.
1 Jan 2024